English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

IN ANY DISCUSSION of key pharmaceutical policyissues, Australia?s National Medicines Policy(NMP) is an important touchstone of whichAustralians can be justly proud. Those familiarwith the stalled evolution of the CanadianNational Pharmaceuticals Strategy and the unevenprovincial patchwork of pharmaceutical coveragein Canada for example, may wonder why it is thata country with longstanding universal health carehas neither universal coverage of medicines nor acohesive national policy framework like Australia?sNMP.One of the fundamental objectives of the NMPis to deliver ?timely access to the medicines thatAustralians need, at a cost individuals and thecommunity can afford?. It also says that ?costshould not constitute a substantial barrier topeople?s access to medicines they need? and thatwhile ?. . . the Pharmaceutical Benefits Scheme(PBS) facilitates access to certain prescribed medicinesby subsidising costs . . . (S)uch subsidiesare not costless, and the community as a wholemust bear them?. Importantly it also says that ?. . .access to medicines should support the rationaluse of those medicines?.

PBS copayments and safety nets - A commentary on Sweeny and Doran and Robertson